BioMarin: EPS Surges Past Expectations

BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results.BioMarin Pharmaceutical (BMRN 1.16%), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped analysts' consensus expectations. Adjusted earnings per share (EPS) reached $0.92, significantly outperforming the anticipated$0.53. Revenue in Q4 hit $747 million, exceeding the estimated$712 million and rising 16% ye ...